Clinical trial · Interventional
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
Surgery and Intracavitary Photodynamic Therapy (PDT) for the Treatment of Malignant Pleural Mesothelioma; The Use of Light Delivery Fibers With Large Diffusers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Combining photodynamic therapy with surgery may be an effective treatment for malignant mesothelioma. PURPOSE: Phase II trial to study the effectiveness of combining photodynamic therapy with surgery in treating patients who have malignant mesothelioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Mesothelioma | Malignant Mesothelioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adjuvant therapy | Procedure | — | UNRESOLVED |
| conventional surgery | Procedure | — | UNRESOLVED |
| porfimer sodium | Drug | Porfimer | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Feasibility
- timeFrame
- 1 month, every 4 months for 2 years, and then every 6 months for 3 years
- measure
- Comparison of results from this regimen to historical controls
- timeFrame
- At completion of study
- measure
- Toxic effects
- timeFrame
- 1 month, every 4 months for 2 years, and then every 6 months for 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed malignant mesothelioma, including the following cell types: * Mixed mesothelial * Sarcomatous * Stage I or II disease using the Butchart system as determined by CT scan or MRI * Disease confined to 1 hemithorax * No tumor involvement of esophagus or heart as evidenced by CT scan * Pericardial or diaphragmatic involvement allowed if disease is limited to the ipsilateral chest * N2 disease allowed if no contralateral pleural involvement * No adenocarcinoma or nonmesothelioma sarcoma of the chest wall PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * Not specified Hematopoietic * WBC greater than 4,000/mm\^3 * Platelet count greater than 100,000/mm\^3 * Hemoglobin greater than 8.5 g/dL (transfusion allowed) Hepatic * Bilirubin less than 3.0 mg/dL * Alkaline phosphatase less than 2 times upper limit of normal (ULN) * SGOT less than 2 times ULN Renal * Creatinine less than 3.0 mg/dL Cardiovascular * No myocardial infarction within the past 6 months Pulmonary * Arterial partial pressure of carbon dioxide (pCO\_2) less than 50 torr at rest * Predicted postoperative FEV\_1 at least 800 mL with maximum oxygen consumption/kg at least 15 mL/min * Predicted postoperative total lung capacity at least 40% of hemoglobin and alveolar ventilation Other * Not pregnant * No other concurrent malignancy except nonmelanoma skin cancer * No contraindication to general anesthetic * No history of porphyria * No indicated sensitivity to porfimer sodium PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * More than 30 days since prior chemotherapy Endocrine therapy * Not specified Radiotherapy * No prior radiotherapy to the chest * No prior radiotherapy for mesothelioma Surgery * Not specified
References
Publications (0)
Data not yet available